Week Ending March 28, 2022

Diabetes Linked To Liver Fibrosis Severity In Patients With HCV
“New findings from a recent study of treatment-naive patients with chronic hepatitis C virus (HCV) infection, specifically those with a high prevalence of obesity, diabetes, and alcohol use in underserved populations, showed an independent relationship between diabetes and liver fibrosis severity.”

Hepatitis C in People of Color: What to Know
“More than 2.5 million Americans live with hepatitis C, a liver infection caused by the virus of the same name. Although hepatitis C affects people of all races and ethnicities, certain groups are disproportionately affected by the virus and develop complications like liver cancer.”

Heavy alcohol use increases liver impairment, risk for HCC in hepatitis-induced cirrhosis
“Among patients with hepatitis-induced cirrhosis, heavy alcohol consumption increased liver function impairment and hepatocellular carcinoma prevalence, according to research.”

The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review
“Since 2010, the Blood Center of Zhejiang province, China, has conducted a pilot nucleic acid amplification testing (NAT) screening of blood donors for Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV). This study aims to assess the results of NAT testing over 10 years to establish the effects and factors influencing NAT yields of HBV, HCV, and HIV.”

Cryoglobulinemia and Other Conditions Related to Hepatitis C Virus
“Hepatitis C is a liver disease, but it can affect your whole body. A hepatitis C virus (HCV) infection starts by causing damage to your liver. Without your liver functioning in a healthy way, you’re at risk for many other health conditions.”

Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol
“By subsidising access to direct acting antivirals (DAAs) for all people living with hepatitis C (HCV) in 2016, Australia is positioned to eliminate HCV as a public health threat. However, uptake of DAAs has declined over recent years and new initiatives are needed to engage people living with HCV in care.”

Disparities in Hepatocellular Cancer Screening in Cirrhotic Patients With Psychiatric Disorders
“Patients with psychiatric disorders are at an increased risk of developing liver diseases, including hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related deaths in the United States. The aim of this study was to re-examine the association of psychiatric illness with HCC and assess its impact on screening practices and the outcomes of HCC.”

1.2 million initiated DAA treatment for HCV between 2014 and 2020
“Approximately 1.2 million people in the United States initiated treatment with direct-acting antivirals for hepatitis C virus infection between 2014 and 2020, more than half of whom were baby boomers, according to a study.”